Join Swanson Reed, UHY Haines Norton and Wrays for a practical workshop that will focus on the problems that every day companies face in protecting, and claiming incentives for their new products.
You will hear from three industry experts on a range of topics, including tax issues, R&D tax incentives and patent protection.
On conclusion of the presentation, participants will have an opportunity to ask the panel any specific questions in a friendly and constructive forum.
|8:30am – 9:00am:||Session 1: Protecting Intellectual Property (IP)||Craig Humphris|
|9:00am – 9:30am:||Session 2: IP & Relevant Tax Considerations||Mark Jeffreson|
|9:30am – 10:00am:||Session 3: R&D Tax Incentives||David Greatwich|
|10:00am – 10:30am:||Session 4: Panel Q&A and Networking Opportunity|
|Craig Humphris||Mark Jeffreson||David Greatwich|
|View Craig’s bio||View Mark’s bio||View David’s bio|
Wednesday, 18th June 2014
8:30am – 10:30am
233 Victoria Square
Register Before: Friday 13th June
Full attendance at this workshop will yield 2 CPE hours towards the Tax Practitioners Board’s (TPB) CPE requirements.
Contact Amy Nolan for more information:
Ph: 08 8121 7850
Mob: 0435 713 493
Are you Eligible to claim R&D? Take our R&D Eligibility Survey and find out.
CBA have announced to the ASX on 18 March that they have entered into a settlement in respect of a tax dispute re: the eligibility of claims for software development R&D activities. Below is an extract from the ASX announcement: Commonwealth Bank of Australia has agreed to withdraw from all current proceedings with the ATO and Innovation and Science Australia (ISA) before the AAT in respect of the eligibility of R&D claims that were made for the years ended 30 […]
To bring a new drug to market, an average of 12 years and $1.7 billion (US) in R&D spending is required. Yet only 1 in 5,000 drugs that begin preclinical testing make it to the market. This has led to a disproportionate number of drugs being developed for rare diseases (affecting less than 200,000 in the US at any given time) due to a 25.3% success rate versus 3.4% for oncology. Many argue this is unsustainable and there is pressure […]